Found: 28
Select item for more details and to access through your institution.
ONC206, an Imipridone Derivative, Induces Cell Death Through Activation of the Integrated Stress Response in Serous Endometrial Cancer In Vitro.
- Published in:
- Frontiers in Oncology, 2020, v. 11, p. N.PAG, doi. 10.3389/fonc.2020.577141
- By:
- Publication type:
- Article
Targeting dopamine receptor D2 as a novel therapeutic strategy in endometrial cancer.
- Published in:
- Journal of Experimental & Clinical Cancer Research (17569966), 2021, v. 40, n. 1, p. 1, doi. 10.1186/s13046-021-01842-9
- By:
- Publication type:
- Article
Methylseleninic acid elevates REDD1 and inhibits prostate cancer cell growth despite AKT activation and mTOR dysregulation in hypoxia.
- Published in:
- Cancer Medicine, 2014, v. 3, n. 2, p. 252, doi. 10.1002/cam4.198
- By:
- Publication type:
- Article
Sorafenib Sensitizes Solid Tumors to Apo2L/TRAIL and Apo2L/TRAIL Receptor Agonist Antibodies by the Jak2-Stat3-Mcl1 Axis.
- Published in:
- PLoS ONE, 2013, v. 8, n. 9, p. 1, doi. 10.1371/journal.pone.0075414
- By:
- Publication type:
- Article
The Akt Inhibitor ISC-4 Synergizes with Cetuximab in 5-FU-Resistant Colon Cancer.
- Published in:
- PLoS ONE, 2013, v. 8, n. 3, p. 1, doi. 10.1371/journal.pone.0059380
- By:
- Publication type:
- Article
Dual Inactivation of Akt and ERK by TIC10 Signals Foxo3a Nuclear Translocation, TRAIL Gene Induction, and Potent Antitumor Effects.
- Published in:
- Science Translational Medicine, 2013, v. 5, n. 171, p. 1, doi. 10.1126/scitranslmed.3004828
- By:
- Publication type:
- Article
Phase I dose escalation and expansion trial of single agent ONC201 in pediatric diffuse midline gliomas following radiotherapy.
- Published in:
- Neuro-Oncology Advances, 2022, v. 4, n. 1, p. 1, doi. 10.1093/noajnl/vdac143
- By:
- Publication type:
- Article
Modulating the unfolded protein response with ONC201 to impact on radiation response in prostate cancer cells.
- Published in:
- Scientific Reports, 2021, v. 11, n. 1, p. 1, doi. 10.1038/s41598-021-83215-y
- By:
- Publication type:
- Article
ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies.
- Published in:
- Science Signaling, 2016, v. 9, n. 415, p. 1, doi. 10.1126/scisignal.aac4380
- By:
- Publication type:
- Article
ONC201 kills solid tumor cells by triggering an integrated stress response dependent on ATF4 activation by specific eIF2α kinases.
- Published in:
- Science Signaling, 2016, v. 9, n. 415, p. 1, doi. 10.1126/scisignal.aac4374
- By:
- Publication type:
- Article
Cancer stem cell-related gene expression as a potential biomarker of response for first-in-class imipridone ONC201 in solid tumors.
- Published in:
- PLoS ONE, 2017, v. 12, n. 8, p. 1, doi. 10.1371/journal.pone.0180541
- By:
- Publication type:
- Article
Anti-Tumor and Anti-Invasive Effects of ONC201 on Ovarian Cancer Cells and a Transgenic Mouse Model of Serous Ovarian Cancer.
- Published in:
- Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.789450
- By:
- Publication type:
- Article
A Bayesian machine learning approach for drug target identification using diverse data types.
- Published in:
- Nature Communications, 2019, v. 10, n. 1, p. N.PAG, doi. 10.1038/s41467-019-12928-6
- By:
- Publication type:
- Article
Correction: Hu, W., et al. Targeting Dopamine Receptor D2 by Imipridone Suppresses Uterine Serous Cancer Malignant Phenotype. Cancers 2020, 12 , 2436.
- Published in:
- 2021
- By:
- Publication type:
- Correction Notice
Targeting Dopamine Receptor D2 by Imipridone Suppresses Uterine Serous Cancer Malignant Phenotype.
- Published in:
- Cancers, 2020, v. 12, n. 9, p. 2436, doi. 10.3390/cancers12092436
- By:
- Publication type:
- Article
First clinical experience with DRD2/3 antagonist ONC201 in H3 K27M-mutant pediatric diffuse intrinsic pontine glioma: a case report.
- Published in:
- Journal of Neurosurgery, 2019, v. 23, n. 6, p. 719, doi. 10.3171/2019.2.PEDS18480
- By:
- Publication type:
- Article
Extracellular Matrix in Synthetic Hydrogel‐Based Prostate Cancer Organoids Regulate Therapeutic Response to EZH2 and DRD2 Inhibitors (Adv. Mater. 2/2022).
- Published in:
- Advanced Materials, 2022, v. 34, n. 2, p. 1, doi. 10.1002/adma.202270014
- By:
- Publication type:
- Article
Extracellular Matrix in Synthetic Hydrogel‐Based Prostate Cancer Organoids Regulate Therapeutic Response to EZH2 and DRD2 Inhibitors.
- Published in:
- Advanced Materials, 2022, v. 34, n. 2, p. 1, doi. 10.1002/adma.202100096
- By:
- Publication type:
- Article
Detection of circulating tumor cells in the cerebrospinal fluid of a patient with a solitary metastasis from breast cancer: A case report.
- Published in:
- 2014
- By:
- Publication type:
- Case Study
Safety and pharmacokinetics of ONC201 (dordaviprone) administered two consecutive days per week in pediatric patients with H3 K27M-mutant glioma.
- Published in:
- Neuro-Oncology, 2024, v. 26, p. S155, doi. 10.1093/neuonc/noae001
- By:
- Publication type:
- Article
ACTION: a randomized phase 3 study of ONC201 (dordaviprone) in patients with newly diagnosed H3 K27M-mutant diffuse glioma.
- Published in:
- Neuro-Oncology, 2024, v. 26, p. S173, doi. 10.1093/neuonc/noae031
- By:
- Publication type:
- Article
Selective DRD2 antagonist and ClpP agonist ONC201 in a recurrent non-midline H3 K27M-mutant glioma cohort.
- Published in:
- Neuro-Oncology, 2024, v. 26, p. S165, doi. 10.1093/neuonc/noae021
- By:
- Publication type:
- Article
Hypothetical generalized framework for a new imaging endpoint of therapeutic activity in early phase clinical trials in brain tumors.
- Published in:
- Neuro-Oncology, 2022, v. 24, n. 8, p. 1219, doi. 10.1093/neuonc/noac086
- By:
- Publication type:
- Article
Epidermal growth factor receptor as a molecular determinant of glioblastoma response to dopamine receptor D2 inhibitors.
- Published in:
- Neuro-Oncology, 2021, v. 23, n. 3, p. 400, doi. 10.1093/neuonc/noaa188
- By:
- Publication type:
- Article
Biological activity of weekly ONC201 in adult recurrent glioblastoma patients.
- Published in:
- Neuro-Oncology, 2020, v. 22, n. 1, p. 94, doi. 10.1093/neuonc/noz164
- By:
- Publication type:
- Article
Correction: First-In-Class Small Molecule ONC201 Induces DR5 and Cell Death in Tumor but Not Normal Cells to Provide a Wide Therapeutic Index as an Anti-Cancer Agent.
- Published in:
- PLoS ONE, 2016, v. 11, n. 2, p. 1, doi. 10.1371/journal.pone.0149365
- By:
- Publication type:
- Article
First-In-Class Small Molecule ONC201 Induces DR5 and Cell Death in Tumor but Not Normal Cells to Provide a Wide Therapeutic Index as an Anti-Cancer Agent.
- Published in:
- PLoS ONE, 2015, v. 10, n. 11, p. 1, doi. 10.1371/journal.pone.0143082
- By:
- Publication type:
- Article
Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway.
- Published in:
- Molecular Cancer, 2015, v. 14, n. 1, p. 1, doi. 10.1186/s12943-015-0346-9
- By:
- Publication type:
- Article